Phase 2a results showed 48.9% six-month progression-free survival versus a 20% historical benchmark, with median overall survival reaching approximately 26 months Houston, Texas (www.wallstreet-pr.com) –

Houston, Texas (www.wallstreet-pr.com) — NeOnc Technologies Holdings (Nasdaq: NTHI) is set up for a potential high impact catalyst day with what market observers are describing

International Regulatory Validation Has Preceded Several Recent FDA Success Stories, Though Significant Development Risks Remain Houston, Texas (www.wallstreet-pr.com) — NeOnc Technologies Holdings (NASDAQ:NTHI) recently achieved

New Funding Structure Includes Redemption Rights, Ownership Limitations, and Conversion Floor as Investors Monitor Upcoming Clinical Updates Houston, Texas (www.wallstreet-pr.com) — NeOnc Technologies Holdings (NASDAQ:NTHI)

NeOnc Technologies Advances Novel Neuro-Oncology Therapies Targeting Glioblastoma and Other Hard-to-Treat Brain Cancers Houston, Texas (www.wallstreet-pr.com) – For years, artificial intelligence has dominated conversations surrounding